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Abstract
Background One quarter of residents in long-term care facilities (LTCFs) have a diagnosis of CHD or stroke and over half 
use at least one preventative cardiovascular medication. There have been no studies that have investigated the longitudinal 
change in secondary preventative cardiovascular medication use in residents in LTCFs over time.
Objective The aim of this study was to investigate the change in cardiovascular medication use among residents with coronary 
heart disease (CHD) and prior stroke in nursing homes (NHs) and assisted living facilities (ALFs) in Finland over time, and 
whether this change differs according to dementia status.
Methods Three comparable cross-sectional audits of cardiovascular medication use among residents aged 65 years and over 
with CHD or prior stroke in NHs in 2003 and 2011 and ALFs in 2007 and 2011 were compared. Logistic regression analyses 
adjusted for gender, age, mobility, cancer and length of stay were performed to examine the effect of study year, dementia 
and their interaction on medication use.
Results Cardiovascular medication use among residents with CHD (NHs: 89% vs 70%; ALFs: 89% vs 84%) and antithrom-
botic medication use among residents with stroke (NHs: 72% vs 63%; ALFs: 78% vs 69%) declined between 2003 and 2011 
in NHs and 2007 and 2011 in ALFs. Decline in the use of diuretics, nitrates and digoxin were found in both groups and 
settings. Cardiovascular medication use among residents with CHD and dementia declined in NHs (88% [95% CI 85–91] in 
2003 vs 70% [95% CI 64–75] in 2011) whereas there was no change among people without dementia. There was no change in 
cardiovascular medication use among residents with CHD in ALFs with or without dementia over time. Antithrombotic use 
was lower in residents with dementia compared with residents without dementia in NHs (p < 0.001) and ALFs (p = 0.026); 
however, the interaction between dementia diagnosis and time was non-significant.
Conclusions The decline in cardiovascular medication use in residents with CHD and dementia suggests Finnish physicians 
are adopting a more conservative approach to the management of cardiovascular disease in the NH population.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 6-019-00656 -x) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Coronary heart disease (CHD) and stroke contribute to 45% 
and 17% of all deaths attributable to cardiovascular disease 
in the United States (US) [1]. One quarter of residents in 
long-term care facilities (LTCFs) have a diagnosis of CHD 
or stroke and over half use at least one preventative car-
diovascular medication [2–4]. Cardiovascular disease is a 
Key Points 
Significant decline in the use of cardiovascular medi-
cations among residents with coronary heart disease 
(CHD) and antithrombotic medications among residents 
with a prior history of stroke in Finnish nursing homes 
(NHs) and assisted living facilities was observed over an 
8-year period.
Decline in the use of cardiovascular medications among 
residents with CHD in NHs may be explained by the 
increasing proportion of residents with dementia.
Findings suggest conservative pharmacological man-
agement of cardiovascular disease among Finnish NH 
residents with dementia and CHD.
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significant contributor to disability, functional decline, com-
plex care requirements and healthcare costs in LTCFs [5, 6].
Between 13 and 74% of residents in LTCFs take nine 
or more regular medications [7]. Half of residents are pre-
scribed antithrombotics and up to 80% are prescribed at least 
one cardiovascular agent [7–9]. Compared with older people 
in the community, residents of LTCFs are less likely to be 
prescribed medications for stroke (aspirin and other anti-
coagulants) and for heart disease [β-blockers, angiotensin-
converting enzyme inhibitors (ACEIs) and aspirin] [10, 11]. 
At least 50% of residents in US and European LTCFs have 
diagnosed dementia. Clinicians may adopt a more conserv-
ative approach to prescribing for residents with dementia 
who they perceive are at a high risk of adverse drug events 
(ADEs) [12, 13]. A palliative approach with focus on opti-
mizing quality of life in LTCF residents with dementia who 
have limited life expectancy has been advocated [14]. This 
trend is evident in US outpatient clinics where antihyper-
tensive prescribing for people aged 65 years and over with 
dementia has remained stable despite an increase in the 
number of people with hypertension [15].
Prescribing recommendations in clinical practice guide-
lines for the secondary prevention of CHD and stroke are 
not specific to patients’ age and setting [16, 17]. The 2011 
American Heart Association (AHA) and American College 
of Cardiology Foundation (ACCF) guidelines and the 2013 
European Society of Cardiology (ESC) guidelines recom-
mend the use of ACEIs or angiotensin II receptor blockers 
(ARBs), β-blockers, statins and antiplatelet agents for the 
secondary prevention of CHD in all populations [16, 18]. 
The 2014 AHA and American Stroke Association (ASA) 
guidelines recommend the use of antithrombotic agents in 
addition to pharmacotherapy to manage risk factors such as 
atrial fibrillation and hypertension [17]. Although the num-
ber of clinical trials including the general older population 
as participants are increasing, the evidence base for manag-
ing CHD and stroke among residents in LTCFs is limited. 
Recent trials investigating antihypertensive therapy specifi-
cally in older people [19] include the Hypertension in the 
Very Elderly Trial (HYVET) and Systolic Blood Pressure 
Intervention Trial (SPRINT) in community-dwelling older 
people aged over 80 and 75 years, respectively [20, 21], and 
the Predictive Values of Blood Pressure and Arterial Stiff-
ness in Institutionalized Very Aged Population (PARTAGE) 
study in LTCF residents aged over 80 years [22]. Although 
evidence is limited and conflicting over the benefit and harm 
of antihypertensive therapy in the frail older population [19], 
their use is recommended after careful consideration of 
comorbidity and potential ADEs [23]. Prescribing decisions 
in LTCFs continue to rely on individualized consideration of 
multimorbidity, polypharmacy, frailty, life expectancy and 
the increased risk of ADEs [24, 25].
Recent studies in European and US LTCFs have explored 
secondary preventative cardiovascular medication use. A 
US study in LTCFs identified 37% of residents were not 
prescribed cardiovascular medications following an acute 
myocardial infarction within 30 days of readmission to the 
LTCF [26]. The Services and Health for Elderly in Long-
Term care (SHELTER) study identified 77.7% of residents 
with CHD received a cardiovascular medication (ACEI or 
ARB, β-blocker, antiplatelet or statin) [3]. Additionally, 
between 24.6 and 60.5% of residents with CHD in Polish 
LTCFs were prescribed either aspirin, β-blockers, ACEI or 
statins [27]. No studies have investigated the longitudinal 
change in secondary preventative cardiovascular medica-
tion use in residents in LTCFs over time. This knowledge 
is needed to determine whether changing attitudes to pre-
scribing in older people with limited life expectancy has 
influenced prescribing [14, 28].
The objective of this study was to investigate the change 
in cardiovascular medication use among residents with 
stroke and CHD in nursing homes (NHs) and assisted liv-
ing facilities (ALFs) in Finland between 2003 and 2011, and 
whether this change differs according to dementia status.
2  Methods
2.1  Study Design, Setting and Source
Data from three previous cross-sectional studies exploring 
nutrition and medication use in NHs and ALFs in Helsinki, 
Finland were combined. The methodology of these stud-
ies has been described previously [29–32]. In brief, data 
were obtained from all residents aged 65 years and over who 
resided permanently in NHs in Helsinki in 2003 (n = 1987) 
and 2011 (n = 1576), and ALFs in 2007 (n = 1377) and 2011 
(n = 1586). Baseline characteristics of the combined dataset 
are reported elsewhere [31]. Data for residents with CHD 
and stroke were extracted from the combined dataset. A total 
of 2012 residents with CHD and 1755 residents with a prior 
history of stroke were included in the current study.
Although the terms ‘LTCF’, ‘NH’ and ‘ALF’ are used 
interchangeably in the literature to define a facility providing 
24-h care to individuals who can no longer reside at home, 
differences in resident and facility characteristics exist inter-
nationally [33]. In this study, NHs are facilities that provide 
24-h care to individuals who have complex care needs that 
can no longer be met in the community [33]. ALFs provide 
similar 24-h care by a registered nurse but in a more home-
like environment, including apartments and group homes 
[31].
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2.2  Study Sample and Data Collection
Trained nurses collected data using the same data collec-
tion tools and methodology across all three studies. Data 
collected included resident demographics, medication infor-
mation and medical diagnoses obtained from the residents’ 
medication charts and medical records. Medication use was 
measured as a point prevalence on the day of data collection.
2.3  Measures and Definitions
All medications were coded using the Anatomical Thera-
peutic Chemical (ATC) classification [34]. All regular pre-
scription and non-prescription medications were recorded. 
Medications were considered to be regular if there was a 
documented regular sequence of administration. Cardiovas-
cular agents included β-blockers (C07), agents acting on the 
renin-angiotensin system (C09), calcium channel blockers 
(C08), diuretics (C03), organic nitrates (C01DA), lipid mod-
ifying agents (C10) and digoxin (C01AA05). Antithrom-
botic agents included warfarin (B01AA03), dipyridamole 
(B01AC07), dipyridamole in combination with aspirin 
(B01AC30) and low-dose aspirin (B01AC06). For combina-
tion products, each active ingredient was counted separately. 
Polypharmacy was defined as the use of nine or more regular 
medications. A resident was considered to have dementia if 
the diagnosis was listed in the medical record or the resident 
used an anti-dementia medication (N06A). The Charlson 
comorbidity index (CCI), a weighted measure incorporating 
up to 19 comorbidities, was calculated for each resident [35]. 
Nutritional status was calculated using the Mini Nutritional 
Assessment (MNA) [36]. A score of < 17 was regarded as 
an indication of risk of malnutrition.
2.4  Statistical Analysis
Analyses were performed separately for residents who had 
a reported history of CHD and prior stroke in NHs between 
the years 2003 and 2011 and in ALFs between 2007 and 
2011. Resident demographics, clinical characteristics and 
cardiovascular medication use across time periods were 
compared using Chi square tests for categorical variables, 
Student’s t-tests for continuous variables and Mann–Whit-
ney U tests for non-parametric continuous variables.
Logistic regression analyses were performed to exam-
ine the effect of study year, dementia and their interaction 
(study year × dementia) on the use of any cardiovascular or 
antithrombotic agent for residents with CHD or stroke in 
NHs and ALFs, respectively. The analyses were adjusted 
for gender, age, mobility, cancer and length of stay in the 
facility, which were deemed to be clinically relevant [9]. 
Adjusted percentages of cardiovascular and antithrombotic 
medication use were estimated from logistic regression 
analyses. All statistical analyses were performed using Stata 
14.1 (StataCorp, College Station, TX, USA).
3  Results
The prevalence of CHD decreased over time in both NHs 
(35.5% in 2003 to 24.5% in 2011) and ALFs (34.4% in 2007 
to 28.2% in 2011) whereas the prevalence of prior history of 
stroke remained constant in NHs (27.2% in 2003 to 28.6% 
in 2011) and in ALFs (25.8% in 2007 to 25.7% in 2011).
3.1  Residents with Coronary Heart Disease
Residents with CHD were older, had greater disability, were 
more likely to be at risk of malnourishment, have demen-
tia and greater comorbidity in both NHs and ALFs in 2011 
compared with respective baselines (Table 1, Supplementary 
Figure S1, see electronic supplementary material [ESM]). 
The prevalence of polypharmacy decreased in NHs (54.4% 
vs 41.2%; p < 0.001) but increased in ALFs (55.0% vs 
62.2%; p = 0.026).
The use of any cardiovascular agent significantly declined 
in both settings among residents with CHD. Significant 
decline in the use of diuretics, nitrates and digoxin were 
identified in NHs in 2011 compared with baseline. Similar 
trends were seen in ALFs concerning nitrates and digoxin. 
The use of any antithrombotic agent and use of low-dose 
aspirin significantly declined in NHs only.
3.2  Residents with a Prior History of Stroke
Residents with a history of stroke were more likely to have 
greater disability and comorbidity in NHs and ALFs in 2011 
compared with baseline (Table 2, Supplementary Figure S2, 
see ESM). Polypharmacy significantly decreased in NHs 
(47.1% vs 37.5%: p = 0.0022).
The use of any antithrombotic agent significantly 
decreased in both NHs and ALFs. Specifically, the use of 
low-dose aspirin and dipyridamole significantly declined 
in both settings. The use of warfarin and statins increased, 
although only significantly in NHs. Reductions in the overall 
use of any cardiovascular agent were observed in both set-
tings among residents with a history of stroke.
3.3  Interaction of Dementia and Study Year 
on Cardiovascular and Antithrombotic Use
Adjusted percentages of cardiovascular and antithrombotic 
medication use in residents with a history of CHD and stroke 
according to dementia status, respectively, are shown in 
Fig. 1. Findings from the logistic regression analyses are 
reported in Supplementary Tables S1 and S2 (see ESM). Of 
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NH residents with CHD, the use of any cardiovascular agent 
decreased over time in those with dementia from 88% (95% 
CI 85–91) in 2003 to 70% (95% CI 64–75) in 2011, whereas 
no difference was found among residents without demen-
tia (91% [95% CI 88–95] in 2003 vs 89% [95% CI 83–95] 
in 2011); p = 0.0017 for study year; p < 0.001 for dementia 
diagnosis; p = 0.050 for their interaction. Although the dif-
ference between cardiovascular medication use in residents 
with and without dementia in ALFs was significant, there 
was no difference in their use over time in residents with 
dementia (87% [95% CI 83–91] in 2007 vs 84% [95% CI 
80–88] in 2011) or without dementia (91% [95% CI 87–95] 
in 2007 vs 91% [95% CI 86–96] in 2011); p = 0.66 for study 
year; p = 0.026 for dementia diagnosis; p = 0.47 for their 
interaction).
Of NH and ALF residents with a prior history of stroke, 
the difference in the use of any antithrombotic agent in resi-
dents with and without dementia was significant, however 
their change in use over time was not. Of NH residents with 
a prior history of stroke, the use of any antithrombotic agent 
decreased over time in residents with dementia from 68% 
(95% CI 63–73) in 2003 to 61% (95% CI 55–66) in 2011 
and without dementia from 81% (95% CI 75–87) in 2003 
to 72% (95% CI 65–80) in 2011 (p = 0.013 for study year,; 
p < 0.001 for dementia diagnosis; p = 0.61 for their inter-
action). In ALFs the respective figures were 74% (95% CI 
67–80) in 2007 versus 67% (95% CI 61–73) in 2011 among 
residents with dementia and 82% (95% CI 76–88) in 2007 
versus 75% (95% CI 68–82) in 2011 for residents without 
dementia (p = 0.036 for study year; p = 0.015 for dementia 
diagnosis; p = 0.81 for their interaction).
4  Discussion
Trends over an 8-year period in Helsinki NHs and ALFs 
reveal significant changes in the use of cardiovascular and 
antithrombotic agents in residents with a history of CHD 
Table 1  Characteristics of residents in nursing homes and assisted living facilities with coronary heart disease
















Demographic and clinical characteristics
 Females, n (%) 569 (80.6) 294 (76.2) 0.086 369 (78.0) 351 (78.5) 0.85
 Education < 8 years, n (%) 368 (59.9) 159 (50.0) 0.004 248 (56.8) 230 (56.2) 0.88
 Mean age (SD) 85.3 (7.0) 86.7 (7.0) < 0.001 84.4 (6.7) 85.9 (6.7) 0.002
 Not able to move independently, n (%) 209 (29.7) 217 (56.2) < 0.001 72 (15.2) 128 (28.6) < 0.001
 Widowed, n (%) 414 (59.2) 214 (56.8) 0.43 294 (62.8) 285 (65.4) 0.43
 MNA, n (%)
  Malnourished (< 17 points) 208 (29.5) 119 (30.8) < 0.001 53 (11.2) 89 (20.0) 0.001
 Charlson comorbidity index (SD) 2.9 (1.2) 2.7 (1.6) < 0.001 2.5 (1.5) 2.7 (1.7) 0.30
 Prior stroke, n (%) 239 (36.8) 121 (31.3) 0.076 147 (31.1) 126 (28.2) 0.33
 Dementia, n (%) 464 (65.7) 305 (79.0) < 0.001 267 (56.4) 314 (70.2) < 0.001
Medication use
 Mean no. of medications (SD) 9.2 (3.4) 8.2 (3.4) < 0.001 8.9 (3.4) 9.8 (3.7) < 0.001
 Polypharmacy (≥ 9 meds), n (%) 384 (54.4) 159 (41.2) < 0.001 260 (55.0) 278 (62.2) 0.026
 Any cardiovascular agent, n (%) 629 (89.1) 270 (69.9) < 0.001 421 (89.0) 376 (84.1) 0.029
 β-blocker, n (%) 292 (41.1) 163 (42.2) 0.78 250 (52.9) 207 (46.3) 0.047
 ACEI/ARB, n (%) 153 (21.7) 103 (26.7) 0.062 180 (38.1) 165 (36.9) 0.72
 Ca channel blocker, n (%) 74 (10.5) 31 (8.0) 0.19 101 (21.4) 60 (13.4) 0.002
 Diuretics, n (%) 419 (59.3) 139 (36.0) < 0.001 254 (53.7) 217 (48.5) 0.12
 Nitrates, n (%) 308 (43.6) 34 (8.8) < 0.001 153 (32.3) 78 (17.4) < 0.001
 Statins, n (%) 20 (2.8) 29 (7.5) < 0.001 101 (21.4) 120 (26.8) 0.051
 Digoxin, n (%) 131 (18.6) 14 (3.6) < 0.001 68 (14.4) 25 (5.6) < 0.001
 Mean no. of cardiovascular medications (SD) 2.0 (1.2) 1.3 (1.2) < 0.001 2.3 (1.5) 2.0 (1.3) < 0.001
 Any antithrombotic agents, n (%) 490 (69.4) 235 (60.9) 0.004 361 (76.3) 327 (73.2) 0.27
 Low-dose aspirin, n (%) 389 (55.1) 153 (39.6) < 0.001 240 (50.7) 203 (45.4) 0.11
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and stroke, respectively. Residents with CHD or stroke and 
co-existing dementia had a lower prevalence in the use of 
any cardiovascular or antithrombotic agent, respectively. 
The decrease in cardiovascular medication use in residents 
with CHD in NHs over time appeared to be explained by the 
increasing proportion of residents with dementia for whom 
conservative prescribing is often advocated.
The prevalence of CHD declined overall in NHs and 
ALFs whereas the prevalence of stroke remained constant. 
In 2011, residents had significantly more disability, malnu-
trition and a higher prevalence of dementia compared with 
prior time points. This suggests that older people are enter-
ing NHs and ALFs frailer and more dependent in activities 
of daily living.
Long-term combination therapy for secondary prevention 
of CHD and risk factors is recommended irrespective of age 
by the AHA/ACCF and ESC guidelines [16, 18]. The use of 
any cardiovascular agent significantly declined in both NHs 
and ALFs, including nitrates and diuretics that may increase 
the risk of falls [37]. Guideline-recommended therapies 
including β-blockers, ACEI/ARBs and low-dose aspirin 
remained < 50% in both settings in 2011. This prevalence is 
lower than in recent studies in US and European NHs, which 
identified secondary preventative medications in approxi-
mately 63% and 77% of residents post-acute myocardial 
infarction and CHD, respectively [3, 26]. The lower preva-
lence found in this study, particularly in the case of antihy-
pertensive agents, reflects the complexity of prescribing in 
Table 2  Characteristics of residents in nursing homes and assisted living facilities with a prior history of stroke
Other agents included clopidogrel, enoxaparin, prasugrel and dalteparin
















Demographic and clinical characteristics
 Females, n (%) 419 (77.4) 327 (72.5) 0.073 255 (71.8) 292 (71.6) 0.94
 Education < 8 years, n (%) 296 (61.2) 181 (50.6) 0.002 192 (58.7) 183 (48.9) 0.01
 Mean age (SD) 82.9 (7.4) 83.2 (7.8) 0.45 82.0 (7.7) 82.8 (7.8) 0.28
 Not able to move independently, n (%) 232 (43.0) 312 (69.2) < 0.001 89 (25.1) 177 (43.4) < 0.001
 Widowed, n (%) 270 (50.4) 223 (49.8) 0.85 197 (57.1) 221 (55.3) 0.61
 MNA, n (%)
  Malnourished (< 17 points) 168 (31.1) 143 (31.7) 0.26 42 (11.8) 104 (25.6) < 0.001
 Charlson comorbidity index (SD) 2.8 (1.2) 3.9 (1.3) < 0.001 3.6 (1.2) 3.9 (1.4) 0.002
 Coronary heart disease, n (%) 239 (44.2) 121 (26.8) < 0.001 147 (41.4) 126 (30.9) 0.003
 Dementia, n (%) 351 (64.9) 304 (67.4) 0.40 196 (55.2) 247 (60.5) 0.14
Medication use
 Mean no. of medications (SD) 8.5 (3.6) 7.7 (3.4) 0.001 8.6 (3.6) 9.1 (3.8) 0.042
 Polypharmacy (≥ 9 meds), n (%) 255 (47.1) 169 (37.5) 0.002 182 (51.3) 222 (54.4) 0.39
 Any cardiovascular agents, n (%) 399 (73.8) 284 (63.0) 0.37 284 (80.0) 282 (69.1) < 0.001
 β-blocker, n (%) 178 (32.9) 155 (34.4) 0.63 148 (41.7) 145 (35.5) 0.081
 ACEI/ARB, n (%) 97 (17.9) 109 (24.2) 0.016 107 (30.1) 128 (31.4) 0.71
 Ca channel blocker, n (%) 62 (11.5) 44 (9.8) 0.39 72 (20.3) 53 (13.0) 0.007
 Diuretics, n (%) 259 (47.9) 129 (28.6) < 0.001 156 (43.9) 151 (37.0) 0.051
 Statins, n (%) 16 (3.0) 45 (10.0) < 0.001 81 (22.8) 94 (23.0) 0.94
 Digoxin, n (%) 70 (12.9) 16 (3.5) < 0.001 45 (12.7) 15 (3.7) < 0.001
 Mean no. of cardiovascular medications (SD) 1.5 (1.3) 1.1 (1.2) < 0.001 1.9 (1.5) 1.5 (1.4) 0.001
 Any antithrombotic agents, n (%) 389 (71.9) 285 (63.2) 0.003 276 (77.7) 280 (68.6) 0.005
 Warfarin, n (%) 66 (12.2) 79 (17.5) 0.018 62 (17.5) 77 (18.9) 0.62
 Dipyridamole, n (%) 66 (12.2) 3 (0.7) < 0.001 18 (5.1) 5 (1.2) 0.002
 Dipyridamole/aspirin, n (%) 40 (7.4) 26 (5.8) 0.31 33 (9.3) 41 (10.0) 0.73
 Low-dose aspirin, n (%) 317 (58.6) 176 (39.0) < 0.001 176 (49.6) 156 (38.2) 0.002
 Other agents, n (%) 3 (0.6) 6 (1.3) 0.20 9 (2.5) 11 (2.7) 0.90
 Mean no. of antithrombotic agents (SD) 0.84 (0.6) 0.6 (0.5) < 0.001 0.7 (0.6) 0.6 (0.5) < 0.001
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this population. Currently, the European Society of Hyper-
tension provides guidance for systolic blood pressure (SBP) 
targets for older people based on evidence from the HYVET 
and SPRINT hypertension trials, which excluded LTCF resi-
dents [23]. It is unclear whether findings from these trials 
could be extrapolated to the LTCF population. The safety of 
combination antihypertensive therapy in LTCF residents has 
recently been questioned with findings from the PARTAGE 
study of 1127 LTCF residents aged over 80 years with low 
SBP (< 130 mmHg) identifying a higher risk of mortality 
with the use of two or more antihypertensive agents [22].
The use of any antithrombotic agent in this study signifi-
cantly declined in both settings, however remained above 
60%. Although prescribing of antithrombotics for stroke 
prevention in older people (≈ 70 years and older) is sup-
ported by the AHA and ASA [17], concerns over bleeding 
risk and under-representation of this population in clini-
cal trials remains in clinical practice [25, 38, 39]. Warfa-
rin, which may be used for the prevention of stroke in the 
setting of atrial fibrillation, increased significantly only in 
NHs. Its overall use was, however, relatively small, poten-
tially due to concern over its monitoring requirements, risk 
of bleeding and concerns for falls [40]. Direct-acting oral 
anticoagulants were not identified in this study; however, 
future studies should investigate the impact of these medica-
tions on the prescribing of warfarin and other anticoagulants. 
Although statin use in NHs increased over time points, its 
use remains low in comparison with recent findings inter-
nationally in Australian [8, 41], Canadian [42] and Euro-
pean [3] NHs, which found a prevalence of up to 40%. A 
review of randomized controlled trials (RCTs) and retro-
spective studies of statin use for secondary prevention in 
community-dwelling older people identified overall benefit 
in reduction of cardiovascular events and mortality in those 
aged ≥ 65 to < 75 years but minimal justification for its use 
in those aged > 85 years [43]. Significant variability in the 
prescribing of statins has been identified, with studies in 
both Australian and Canadian NHs finding fewer statins 
prescribed for frail NH residents compared with non-frail 
residents [27, 42].
The proportion of residents with dementia increased 
over time in our study with > 60% of residents with CHD 
and stroke having a dementia diagnosis across settings in 
2011. Among residents with CHD in NHs, the change in 
cardiovascular medication use over time was moderated by 
dementia, indicating conservative prescribing in this popu-
lation. Although the severity of dementia for residents in 
this study was unclear, increased care requirements for resi-
dents residing in NHs compared with ALFs, which provide 
a more home-like environment, may indicate greater sever-
ity of dementia in this setting. Findings from this study are 
comparable to findings in the US community setting that 
found older adults with dementia were less likely to be pre-
scribed secondary preventative medications for CHD than 
those without [44]. Prescribing of antithrombotics in NHs 
and ALFs was lower among residents with dementia than 
among those without dementia, indicating selective prescrib-
ing and deprescribing according to residents’ clinical and 
frailty status.
Fig. 1  Adjusted (gender, age, mobility, cancer and length of stay in the facility) use of cardiovascular and antithrombotic agents in residents with 
a history of coronary heart disease and stroke according to dementia, respectively
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Increasing attention among clinicians on the rationali-
zation of medications that may no longer be of benefit in 
residents with limited life expectancy and dementia has 
given rise to recommendations to improve appropriate pre-
scribing in this population [14]. This includes advocacy 
for a palliative approach in residents with dementia with a 
focus on optimizing quality of life [14]. Consensus criteria 
by Holmes et al. has identified varying degrees of appro-
priateness of cardiovascular and antithrombotic agents in 
people with advanced dementia [14]. These included the 
use of β-blockers, calcium channel blockers, diuretics and 
ACEI/ARBs classified as sometimes appropriate; warfa-
rin and antiarrhythmic agents including digoxin as rarely 
appropriate; and lipid-lowering medications and antiplatelet 
agents (excluding aspirin) as never appropriate [14]. Despite 
the availability of these consensus criteria, there is limited 
evidence from RCTs to inform appropriate medication use 
in this population. The apparent decline in adherence to 
guideline-recommended pharmacotherapy for the secondary 
prevention of CHD and stroke may represent good clinical 
practice and greater consideration for the ongoing risk and 
benefit of these medications in residents with limited life 
expectancy at high risk of adverse events.
There is currently minimal guidance for secondary pre-
vention of CHD and stroke for frail older residents in LTCFs 
[24]. Instead, clinicians balance the risk of adverse events 
with the benefits in terms of preventing subsequent myo-
cardial infarction and stroke and the impact on residents’ 
quality of life. Although the AHA and ESC broadly sup-
port the use of secondary preventative medications in older 
people over 65 years with CHD and stroke [18, 24, 45, 46], 
there is an increasing view that their use may no longer be 
appropriate for residents with limited life expectancy and in 
LTCFs [28, 47]. Recently, the importance of research into 
prescribing patterns in vulnerable patient groups, such as 
those residing in NHs with dementia and limited life expec-
tancy, has been emphasized [14, 48]. Increasing inclusion 
of these populations in studies examining the use of second-
ary preventative medications is required to inform evidence-
based guidelines and recommendations in this population. 
Future studies should additionally explore the impact of the 
changes in prescribing of secondary preventative medica-
tions on outcomes including subsequent myocardial infarc-
tion, stroke and mortality.
4.1  Strengths and Limitations
This study utilized a large and representative sample size 
of residents from NHs and ALFs in Helsinki, Finland. The 
original sample comprised > 80% of all residents over the 
age of 65 years in NHs and over 60% in ALFs [31]. Data 
were collected by trained nurses using the same protocol 
at all three time points. Medication use was defined as a 
point prevalence on the date of data collection using each 
resident’s medication chart. This ensured we analysed actual 
medication use rather than prescribing or dispensing of med-
ications. However, the use of point prevalence data limits 
our understanding of long-term medication usage over time 
and longitudinal data is required to explore this further. It is 
unclear when medications were commenced with respect to 
diagnoses. Cardiovascular medications may have also been 
prescribed for clinical indications other than CHD or stroke. 
The severity of dementia was not determined. This study did 
not investigate potential prescriber or facility-level factors 
that may have contributed to prescribing variability.
5  Conclusion
Declines in cardiovascular medication use in residents with 
CHD and dementia over time suggest Finnish physicians 
are adopting a more conservative approach to the manage-
ment of cardiovascular disease in the NH population with 
dementia. Future research should explore the impact of these 
changes on outcomes in this population. There is a need 
for RCTs to further inform appropriate medication use in 
LTCFs.
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